Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 12/20 | 1.00 |
| ▸ | PIM1 | P11309 | 9/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.59 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 3/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394851 | 1.00 | PIM3 (1.00) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL844836 | 0.83 | PIM3 (0.70) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL845204 | 0.83 | PIM3 (0.70) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL14519078 | 0.80 | PIM3 (0.65) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL844512 | 0.80 | PIM3 (1.00) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL844626 | 0.80 | PIM3 (1.00) | PIM3PIM1PIM2CYP2A6TRIM24 | |
| SCHEMBL10079034 | 0.79 | PIM3 (0.71) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL844850 | 0.79 | PIM3 (1.00) | PIM3PIM1PIM2CYP2A6TRIM24 | |
| SCHEMBL844940 | 0.79 | PIM3 (0.76) | PIM3PIM1PIM2CYP2A6IMPDH2 | |
| SCHEMBL844957 | 0.78 | PIM3 (1.00) | PIM3PIM1PIM2CYP2A6IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | claimed |
| EP-2326649-B1 | NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-03-28 | — | — | EP | claimed |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) | 2011-10-27 | — | — | US | claimed |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS PHARMA AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | NOVARTIS AG (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-107667092-B | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | 诺华股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481586-B2 | Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-07-09 | — | — | US | disclosed |
| EP-2326649-B1 | NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-03-28 | — | — | EP | disclosed |
| EP-2326649-B1 | NOVEL PYRROLO[2,3-a]CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-03-28 | — | — | EP | disclosed |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) | 2011-10-27 | — | — | US | disclosed |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) | 2011-10-27 | — | — | US | disclosed |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | UNIVERSITE BLAISE PASCAL-CLERMONT-FERRAND II (FR) | 2011-10-27 | — | — | US | disclosed |
| WO-2010000978-A1 | NOVEL PYRROLO [2,3-A] CARBAZOLES AND USE THEREOF AS PIM KINASE INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | PIM3 810/4885PIM1 584/4885PIM2 706/4885 |
| US-20230321285-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, IL15, CD274 | PIM3 588/4885PIM1 578/4885PIM2 1471/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | PIM3 786/4885PIM1 537/4885PIM2 656/4885 |
| US-20110263669-A1 | Novel Pyrrolo [2,3-A] Carbazoles and Use Thereof as PIM Kinase Inhibitors | PIM3, PIM1, PIM2 | PIM3 1/4885PIM1 2/4885PIM2 3/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | PIM3 786/4885PIM1 537/4885PIM2 656/4885 |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | PIM3 786/4885PIM1 537/4885PIM2 656/4885 |
| US-20230338587-A1 | METHOD OF TREATING PSMA-EXPRESSING CANCERS | IL15RA, CD274, IL15 | PIM3 459/4885PIM1 506/4885PIM2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.